Physician profile
Scott Mitchell Thomas
NPI 1144273939
$12,105.44
in general payments reported to CMS, 2019-2025
43 companies · $1,127 in 2025
The $1,127 reported for 2025 was more than what 88% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,435 · 2020: $1,495 · 2021: $2,056 · 2022: $1,541 · 2023: $1,162 · 2024: $2,290 · 2025: $1,127.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,579.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,578.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,666.14 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Novo Nordisk INC | $1,568.98 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $1,519.05 | 2019-2025 | Jardiance, Zepbound, Mounjaro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $934.05 | 2019-2025 | Jardiance, Synjardy |
| Abbvie INC. | $886.56 | 2019-2025 | Vraylar, Ubrelvy |
| Pfizer INC. | $479.34 | 2020-2025 | |
| Biotissue Holdings INC. | $436.87 | 2019-2025 | |
| Si-Bone, INC. | $405.33 | 2019-2024 | |
| Amarin Pharma, INC. | $402.82 | 2019-2023 | |
| Allergan, INC. | $349.13 | 2019-2021 | |
| Idorsia Pharmaceuticals US INC | $265.69 | 2023-2025 | Quviviq, Quviviq |
| Glaxosmithkline, LLC. | $261.26 | 2019-2024 | Arexvy, Shingrix, Pediarix |
| Takeda Pharmaceuticals U.S.A., INC. | $248.93 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $242.77 | 2019-2025 | Vaxneuvance, Gardasil 9, Capvaxive |
| Biohaven Pharmaceuticals, INC. | $241.85 | 2021 |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.